By Fineline Cube 
China-based 3D Medicines (HKG: 1244) has entered into a strategic cooperation framework agreement with CATUG Biotechnology. The collaboration aims to leverage 3D Medicines’ advanced mRNA technology and LNP delivery platforms, combined with CATUG’s expertise in large-scale mRNA production, to advance developments in targeted LNP delivery, cancer vaccines, and in vivo CAR-T/NK therapies.
Collaboration Details
3D Medicines will utilize its AI-driven mRNA technology platform (3D-PreciseAg) for antigen analysis and neoantigen selection, alongside its AI-enhanced LNP delivery system (3D-LNP) to boost delivery efficiency and targeting precision. CATUG Biotechnology will contribute its end-to-end CRDMO platform, which encompasses GMP-grade DNA template preparation, RNA synthesis, LNP development, and final product manufacturing, all compliant with FDA/EMA/NMPA guidelines.
Regulatory and Commercial Advantages
CATUG’s Suzhou facility, having passed EU QP audits, is positioned to support dual regulatory filings in China and the U.S., facilitating the clinical trials and commercialization of 3D Medicines’ mRNA-LNP-based pipelines. This strategic partnership is set to drive innovation and market expansion in the mRNA-LNP therapy space.-Fineline Info & Tech